Clinical Trials Browser

Graft vs Host Disease, Lymphoma, Non-Hodgkin, Multiple Myeloma, Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Clinical Trials

Chidamide Bridging for CAR-T Therapy

Relmacabtagene Autoleucel as First-Line Therapy for High-Risk Large B-Cell Lymphoma

CD70-targeted CAR-NKT Cells(CGC729) Therapy in the Renal Cell Carcinoma

VICTORY

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Treatment of Advanced Solid Tumors With Neo-T(GI-NeoT-02)

Safety, Efficacy and Pharmacokinetics of ThisCART19A in Patients With Refractory or Relapsed B Cell Lymphoma

CD19 T-CAR for Treatment of Children and Young Adults With r/r B-ALL

Clinical Study of XPO-1 Inhibitors Plus CAR-T Cells in Relapsed Refractory B-cell Non-Hodgkin's Lymphoma

Novel BCMA-targeted CAR-T Cell Therapy for Multiple Myeloma

Natural Killer (NK) Cell Therapy Targeting CD33 in Acute Myeloid Leukemia

Natural Killer(NK) Cell Therapy in r/r AML

EBV CAR-T Cells for Nasopharyngeal Carcinoma

BGT007 Cell Treatment of Nasopharyngeal Carcinoma

Cladribine Combined With G-CSF and Cytarabine as a Salvage Treatment in R/R ALL

T Cell Transfer With or Without Dendritic Cell Vaccination in Patients With Melanoma

B7-H3 Targeting CAR-T Cells Therapy for B7-H3 Positive Solid Tumors

Natural Killer (NK) Cell Therapy for B-Cell Malignancies

Orelabrutinib and Obinutuzumab Plus FC Regimen in Treating Newly Diagnosed CLL/SLL

ZFCR/ZBR

Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies

A Clinical Trial to Assess the Efficacy and Safety of the Combination of a Drug Call Quizartinib With Chemotherapy (FLAG-IDA) in Patients With Acute Myeloid Leukemia That Has Not Responded to the First Treatment or That Has Returned After the First Treatment

Anti-CD33 CAR NK Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

Anti-BCMA CAR-NK Cell Therapy for the Relapsed or Refractory Multiple Myeloma

Venetoclax Combining With Fludarabine and Melphalan as Conditioning Regimen for Allo-HSCT

PALG-AML1/2016

Dual CD33-CLL1-CAR-T Cells in the Treatment of Relapsed/Refractory Acute Myeloid Leukemia

The Fourth Generation CART-cell Therapy for Refractory-Relapsed Ovarian Cancer

Anti-CD7 U-CAR-T Cell Therapy for T/NK Cell Hematologic Malignancies

Cord Blood Derived Anti-CD19 CAR-Engineered NK Cells for B Lymphoid Malignancies

Universal Chimeric Antigen Receptor-modified AT19 Cells for CD19+ Relapsed/Refractory Hematological Malignancies

Haploidentical Stem Cell Transplantation in Neuroblastoma

Clinical Study of CAR-BCMA T Cells in Patients With Refractory or Relapsed Multiple Myeloma

Clinical Study of Redirected Autologous T Cells With a Chimeric Antigen Receptor in Patients With Malignant Tumors

Clinical Study of CAR-BCMA T in Patients With Refractory or Relapsed Multiple Myeloma

NK Cell Infusion for Patients With Acute Myeloid Leukemia

Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy

Anti-CD19 U-CAR-T Cell Therapy for B Cell Hematologic Malignancies

Anti-CD19 CAR T Infusion Combined With Allogeneic Stem Cell Transplantation for B-cell Leukemia/Lymphoma

CRISPR (HPK1) Edited CD19-specific CAR-T Cells (XYF19 CAR-T Cells) for CD19+ Leukemia or Lymphoma.

a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

MESO-CAR T Cells Therapy for Relapsed and Refractory Epithelial Ovarian Cancer

MESO-CAR T Cells Therapy for Relapsed and Refractory Ovarian Cancer

BCMA Chimeric Antigen Receptor Expressing T Cells in Multiple Myeloma

NY-ESO-1 TCR （TAEST16001）for Patients With Advanced NSCLC

Investigator Initiated Phase 1 Study of TBI-1301

TBF-Cord

Study of Fludarabine With Pegylated Liposomal Doxorubicin Versus Pegylated Liposomal Doxorubicin Alone In Patients With Platinum Resistant/Refractory Ovarian Cancer

Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell Lymphoma

NRT-01